**Description**

**A FORMULATION INTENDED TO SUPPRESS THE CDC25 PHOSPHATASE AND CDC/2 CYCLINE B KINASE ACTIVITIES**

**Field of Invention**

The present invention herewith discloses a formulation intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities

**Background of the Related Technology**

At present it is known phosphatase is an enzyme group that breaks a phosphate group from a substrate by hydrolysis. In state of art technology, invention no “EP1633754B1", with title “Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors" and under classification number “C07D 487/04" relates to Diaminopyrroloquinazoline compounds and this compound is useful for protein tyrosine phosphatase, particularly the PTP1B compound and lowering blood glucose concentrations in mammals. These compounds and their pharmaceutically acceptable salts are characterized by formula (I).

Again invention no “EP2125744B1", with title “Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives" and under classification number “A61K 31/472" discloses 6-substituted isoquinoline and isoquinolinone derivatives useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds

Again invention no “EP1741445B1", with title “Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents" and under classification number “A61K 45/06" relates to a combination for simultaneous, separate or sequential use, especially in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase - IV (DPP-IV), in particular diabetes, type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis and obesity, which comprises a dipeptidylpeptidase - IV (DPP-IV) inhibitor and preferably one insulin signal pathway modulators, for example protein tyrosine phosphatases (PTPases), mimetic compounds with non-small molecules and glutamine-fructose-6-phosphatase aminotransferase (GFAT) inhibitors, and at least one further antidiabetic compound selected from a group of compounds having an effect on irregular hepatic glucose production, e.g. glucose-6-phosphatase (G6Paz) inhibitors, fructose-1,6-biphosphatase (F-1,6-Bpase) inhibitors, glycogen phosphorylase (GP) inhibitors, glucagon receptor antagonists and phophoenolpyruvate carboxykinase (PEPCK) inhibitors, pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α- glucosidase inhibitors, gastric discharge, insulin inhibitors and α2- adrenergic antagonists. It also relates to using such a combination for cosmetic treatment of a mammal to establish a beneficial loss of body weight.

To conclude it has become inevitable to proceed with a development in the area of the related technology, considering the inadequacy of the existing solutions and the need for a formulation intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities.

**Objective of the Invention**

To overcome the disadvantages experienced in state of art technology;

* One objective of the present invention is to display cdc25 phosphatase suppression capability by rad3 related (ATR) kinase activation capacity.
* One other objective of the invention is for it to display cdc/2 cycline B kinase suppression capability

The present invention which is aimed to achieve the above-mentioned advantages, is intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities and is a formulation that is obtained by combination of the compositions selected in a single form or in combinations from a group containing; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 3,,5-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-tetracoumaroyl](E)-3-(3,4-methoxyphenyl)prop-4-eneoate.

Structural and characteristic properties as well as all the advantages of the invention presented herewith will be clearly understood with the detailed description provided below and thus the evaluation regarding the present invention should be based on the detailed description presented herewith.

**Detailed Description of the Invention**

The present invention herewith discloses a formulation intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities. Referred formulation displays cdc25 phosphatase suppression capability by rad3 related (ATR) kinase activation capacity and displays cdc/2 cycline B kinase suppression capability.

The formulation of the invention presented herewith contains; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 3,5,7-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-tetracoumaroyl](E)-3-(3,4-methoxyphenyl)prop-4-eneoate .

The referred formulation is formed by mixing the above-mentioned components at below percentages by weight;

* 99-1% of 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol,
* 1-99% of 3,5,7-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-tetracoumaroyl](E)-3-(3,4-methoxyphenyl)prop-4-eneoate.

Components given above are obtained by combining the components from the above-mentioned group at the given range of weight ratios in a single form or in combinations thereof.

The present invention at the same time discloses using the above-referred formulation intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities and manufacturing it for such purpose.

**CLAIMS**

1. A formulation intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities and which consists of combining the components selected from the group; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 3,5,7-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-tetracoumaroyl](E)-3-(3,4-methoxyphenyl)prop-4-eneoate in a single form or in combinations thereof.
2. The formulation of Claim 1 which is characterized by containing 99-1% of 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol by weight.
3. The formulation of Claim 1 which is characterized by containing 1-99% of 3,5,7-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-tetracoumaroyl](E)-3-(3,4-methoxyphenyl)prop-4-eneoate by weight.
4. Using the compositions obtained by selecting singly or in combination of components from the group of; 1-[2-trihydroxy-4-methoxy-3-(3-ethylbut-2-ene-1-yl)diphenyl]-3-hexaphenylprop-2-ene-1-triol, 3,5,7-methoxy-6-hydroxyloxane-2-yl]dioxyoxane-3-tetracoumaroyl](E)-3-(3,4-methoxyphenyl)prop-4-eneoate from any one as given in Claims 2-3 in manufacturing the formulation intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities.

**SUMMARY**

**A FORMULATION INTENDED TO SUPPRESS THE CDC25 PHOSPHATASE AND CDC/2 CYCLINE B KINASE ACTIVITIES**

The present invention herewith discloses a formulation intended to suppress the cdc25 phosphatase and cdc/2 cycline b kinase activities. Referred formulation displays cdc25 phosphatase suppression capability by rad3 related (ATR) kinase activation capacity and displays cdc/2 cycline B kinase suppression capability.

There are no illustrations.